Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Recursion Pharmaceuticals Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.47 (market cap $746.48M), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.9× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FEPI | RXRX | |
|---|---|---|
Market Cap | $746.48M | $2.14B |
Volume | 334,337 | 30,789,535 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $6.79 |
52-Week Low | $37.98 | $2.84 |
Typical Hold Time | 56 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.59, down 0.17% on the day, with a bullish technical signal supported by moving averages. The ETF employs a covered call strategy on AI and tech mega-caps, generating weekly dividends averaging $0.20-0.21 per share. Recent news highlights its high yield but notes underperformance versus peers in total return.
Outlook: High income potential via dividends but capped upside from call-writing. Risks include concentrated tech exposure, volatility sensitivity, and competitive pressure from alternative yield strategies. Neutral sentiment prevails amid yield appeal and growth constraints.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
